Skip to content
AnalystLens

Medline 8-K Report, Financial Results (Feb 25, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 25, 2026
Period End
February 25, 2026
Security
MDLN
In the record · 2025–202610-K110-Q28-K10

MDLN filed 1 annual reports (10-K), 2 quarterly reports (10-Q) and 10 current reports (8-K) between 2025 and 2026.

  1. Leadership change8-K · Dec ’25Dec ’25
  2. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 25, 2026. Cited figures are marked; the original filing is the authoritative source.

Medline Inc. (Nasdaq: MDLN) reported fourth quarter and full year 2025 results on February 25, 2026, the first earnings release following its IPO, which was completed in the fourth quarter of 2025.

Full-year net sales rose 11.5% to $28.4 billiona, with Organic Sales up 10.5%, driven mainly by volume growth in both the Medline Brand and Supply Chain Solutions segments. Full-year Adjusted EBITDA grew 3.2% to $3.5 billion, but net income fell 3.6% to $1.2 billion as tariff-related cost of goods sold and higher operating costs, including headcount investments and IPO-related expenses, weighed on profitability. Fourth-quarter Adjusted EBITDA was roughly flat at $805 million, and Q4 net income declined 37.7% to $180 million, reflecting margin compression from tariffs and higher costs.

Balance sheet and cash generation improved meaningfully. Net debt fell about 35% to $10.8 billionb, and net leverage dropped to 3.1x from 4.9x a year earlier, helped by IPO proceeds and debt repayment. Free Cash Flow was $1.3 billion for 2025, down 8.3% year over year, as operating cash flow was roughly flat and capital expenditures rose on distribution center automation and kitting facility investments.

Management guided 2026 Organic Sales growth of 8% to 9% and Adjusted EBITDA of $3.5 to $3.6 billionc, implying modest Adjusted EBITDA growth versus 2025. For investors, the key tension is top-line momentum and deleveraging versus margin pressure from tariffs and rising costs.

Gross margin fell to 26.4% from 27.3%, and the 2026 EBITDA guide implies limited expansion, so the investment case depends on tariff mitigation, operating leverage from new customer signings ($2.4 billiond in total new annual contract value in 2025), and continued debt reduction. The new tax receivable agreement liability of $3.5 billion and the dual-class structure are also worth monitoring.

02—Key points

Key Highlights

  1. Full-year 2025 net sales of $28.4 billion, up 11.5%, with Organic Sales up 10.5%; Q4 net sales of $7.8 billion, up 14.8%
  2. Full-year 2025 Adjusted EBITDA of $3.5 billion (up 3.2%), while Q4 Adjusted EBITDA was flat at $805 million and Q4 net income fell 37.7% to $180 million
  3. Gross margin compressed to 26.4% from 27.3% for the full year, driven by tariff-related costs of goods sold and higher operating expenses
  4. Net leverage improved sharply to 3.1x from 4.9x, with net debt down 34.7% to $10.8 billion following the IPO and debt reduction
  5. Free Cash Flow of $1.3 billion for 2025, down 8.3%, as capital expenditures rose to $447 million on distribution automation and kitting investments
  6. 2026 guidance: Organic Sales growth of 8% to 9% and Adjusted EBITDA of $3.5 to $3.6 billion
  7. Completed IPO in Q4 2025; recorded a $3.5 billion tax receivable agreement liability and $2.4 billion in total new customer signings for 2025

03—Questions

Frequently Asked Questions

  1. How did Medline perform financially in 2025?

    Medline grew full-year net sales 11.5% to $28.4 billion and Adjusted EBITDA 3.2% to $3.5 billion. Net income declined 3.6% to $1.2 billion due to tariff-related cost of goods sold, higher operating costs, and IPO-related expenses.

  2. Why did fourth-quarter net income fall so sharply?

    Q4 net income dropped 37.7% to $180 million, reflecting higher cost of goods sold from tariffs, increased headcount investments, and IPO-related expenses, partially offset by higher net sales. Q4 gross margin fell to 24.6% from 27.3%.

  3. What is Medline's 2026 outlook?

    Management guided to Organic Sales growth of 8% to 9% and Adjusted EBITDA of $3.5 to $3.6 billion for full-year 2026. The guidance implies only modest EBITDA growth, so margin recovery will be a key focus.

  4. How strong is Medline's balance sheet after the IPO?

    Net debt fell to $10.8 billion from $16.6 billion, and net leverage dropped to 3.1x from 4.9x. Cash rose to $1.9 billion. However, the company now carries a $3.5 billion tax receivable agreement liability.

  5. What risks should investors watch?

    Key risks include tariff-driven cost pressure on gross margin, rising operating costs, capital intensity of distribution automation, reliance on large healthcare customers and GPOs, cybersecurity exposure, and the dual-class share structure.

04—Continue

← View all 8-K filings